Results 241 to 250 of about 75,341 (263)
Some of the next articles are maybe not open access.

Treatment-Resistant Schizophrenia

Psychiatric Clinics of North America, 2016
Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy. In terms of the underlying mechanisms of the development of TRS, progress has been made for the elucidation of the neurochemical ...
Helio, Elkis, Peter F, Buckley
openaire   +2 more sources

Treatment-Resistant Schizophrenia

The Journal of Clinical Psychiatry, 2021
Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of sufficient dose, duration, and adherence. Several demographic, clinical, and neurologic predictors are associated with TRS.
Correll, Christoph U., Howes, Oliver D.
openaire   +3 more sources

Treatment-Resistant Schizophrenia

The Journal of Clinical Psychiatry, 2019
A significant minority of patients (about one quarter to one third) will have a poor response to first-line antipsychotics and be considered treatment-resistant. In this chapter, I outline a sequential approach to treatment-resistant schizophrenia.
openaire   +3 more sources

Treatment-Resistant Schizophrenia

Psychiatric Clinics of North America, 2007
This article opens with a brief history of pharmacologic treatment of schizophrenia. It then discusses the definition and treatment of treatment-resistant schizophrenia, with particular attention to clinical, biological and neuroimaging correlates, as well as the best treatment options, including the use of clozapine in patients who meet the definition
openaire   +2 more sources

Treatment resistance in schizophrenia

Psychiatry, 2005
Abstract In a substantial proportion of people with schizophrenia the illness shows a poor response to antipsychotic medication. Failure to achieve remission even after the first episode is limited to relatively few cases, and more commonly patients become progressively unresponsive to medication.
Thomas R.E. Barnes, Serdar Dursun
openaire   +1 more source

Management of treatment resistance in schizophrenia

Biological Psychiatry, 2001
A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of the second-generation antipsychotics. The need for accurate evaluation will increase further as other new antipsychotic medications are developed. Patients with schizophrenia may manifest poor
R R, Conley, D L, Kelly
openaire   +2 more sources

Drug Strategies and Treatment-Resistant Schizophrenia

Australian & New Zealand Journal of Psychiatry, 1996
Objectives: The aims of the paper are to review the notion of treatment resis- tance in schizophrenia and consider the factors important in determining non- responsiveness to standard neuroleptic treatment, and to review the strategies currently available in the treatment of such patients, including an evaluation of recently-introduced, novel drug ...
C, Pantelis, T R, Barnes
openaire   +2 more sources

Cannabidiol monotherapy for treatment-resistant schizophrenia

Journal of Psychopharmacology, 2006
Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana's typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data (Zuardi et al., 2002). In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients ...
Antonio Waldo, Zuardi   +6 more
openaire   +2 more sources

Managing patients with “treatment‐resistant” schizophrenia

Medical Journal of Australia, 2003
Patients who fail to respond adequately to pharmacological treatment present an ongoing therapeutic challenge. The term "incomplete recovery" (IR) is preferred to the current term "treatment resistance" to describe these patients. IR should be considered from a multidimensional perspective that includes a broad range of symptoms and functional ...
Christos, Pantelis, Timothy J R, Lambert
openaire   +2 more sources

[Treatment-resistant schizophrenia].

Revue medicale de Bruxelles, 2014
Schizophrenia is a psychiatric disorder that causes severe cognitive, behavioral and social dysfunction, responsible for a shortening of the life expectancy of patients, with an increased risk of suicide, cardiovascular disease and cancer. The management of patient with schizophrenia is global and atypical antipsychotics, antagonizing dopamine pathway,
openaire   +1 more source

Home - About - Disclaimer - Privacy